This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Nov 26;59(10):1482-3.

doi: 10.1212/wnl.59.10.1482.

Needed in MS: evidence, not EVIDENCE

Karl Kieburtz¹, Michael McDermott

Affiliations

PMID: 12451186
DOI: 10.1212/wnl.59.10.1482

Comment

Needed in MS: evidence, not EVIDENCE

Karl Kieburtz et al. Neurology. 2002.

. 2002 Nov 26;59(10):1482-3.

doi: 10.1212/wnl.59.10.1482.

Authors

Karl Kieburtz¹, Michael McDermott

Affiliation

¹ Department of Neurology, University of Rochester Medical Center, NY 14642, USA. kkieburtz@mct.rochester.edu

PMID: 12451186
DOI: 10.1212/wnl.59.10.1482

No abstract available

PubMed Disclaimer

Comment in

When marketing and science intersect: do patients with MS benefit?
Lublin FD. Lublin FD. Neurology. 2002 Nov 26;59(10):1480-1. doi: 10.1212/wnl.59.10.1480. Neurology. 2002. PMID: 12451185 No abstract available.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial.
Byrne E. Byrne E. Neurology. 2003 Jun 10;60(11):1872; author reply 1872-3. Neurology. 2003. PMID: 12796564 Clinical Trial. No abstract available.

Comment on

When marketing and science intersect: do patients with MS benefit?
Lublin FD. Lublin FD. Neurology. 2002 Nov 26;59(10):1480-1. doi: 10.1212/wnl.59.10.1480. Neurology. 2002. PMID: 12451185 No abstract available.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B; EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Panitch H, et al. Neurology. 2002 Nov 26;59(10):1496-506. doi: 10.1212/01.wnl.0000034080.43681.da. Neurology. 2002. PMID: 12451188 Clinical Trial.
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. Clanet M, et al. Neurology. 2002 Nov 26;59(10):1507-17. doi: 10.1212/01.wnl.0000032256.35561.d6. Neurology. 2002. PMID: 12451189 Clinical Trial.

Similar articles

Betaseron for multiple sclerosis. Implications for therapeutics.
Rudick RA. Rudick RA. Arch Neurol. 1994 Feb;51(2):125-8. doi: 10.1001/archneur.1994.00540140027011. Arch Neurol. 1994. PMID: 8304836 No abstract available.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial.
Byrne E. Byrne E. Neurology. 2003 Jun 10;60(11):1872; author reply 1872-3. Neurology. 2003. PMID: 12796564 Clinical Trial. No abstract available.
[Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL, Khachanova NV, Davydovskaia MV, Popova NF, Gusev EI. Demina TL, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):24-6. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID: 18567192 Review. Russian. No abstract available.
Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
Río J, Montalban X. Río J, et al. Neurology. 2000 Apr 25;54(8):1710. doi: 10.1212/wnl.54.8.1710. Neurology. 2000. PMID: 10762530 No abstract available.
Pharmacological treatment of early multiple sclerosis.
Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. Stüve O, et al. Drugs. 2008;68(1):73-83. doi: 10.2165/00003495-200868010-00005. Drugs. 2008. PMID: 18081373 Review.

See all similar articles

Cited by

[Interferon β for multiple sclerosis. How much is good enough?].
Warnke C, Leussink VI, Kieseier BC, Hartung HP. Warnke C, et al. Nervenarzt. 2010 Dec;81(12):1476-82. doi: 10.1007/s00115-010-3017-5. Nervenarzt. 2010. PMID: 21104222 Review. German.
What can we learn from failed clinical trials in multiple sclerosis?
Ziemssen T. Ziemssen T. J Neurol. 2008 Dec;255 Suppl 6:97-101. doi: 10.1007/s00415-008-6018-6. J Neurol. 2008. PMID: 19300968
Multiple sclerosis therapy: an update on recently finished trials.
Kleinschnitz C, Meuth SG, Stüve O, Kieseier B, Wiendl H. Kleinschnitz C, et al. J Neurol. 2007 Nov;254(11):1473-90. doi: 10.1007/s00415-007-0684-7. Epub 2007 Nov 15. J Neurol. 2007. PMID: 18004638 Review.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC. Warnke C, et al. Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627. Drug Des Devel Ther. 2010. PMID: 20689698 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information